Allegria Therapeutics AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Allegria Therapeutics AG - overview
Established
2023
Location
Basel, -, Switzerland
Primary Industry
Biotechnology
About
Founded in 2023 and based in Switzerland, by Co-founder and CEO Maria Van Dongen, Allegria Therapeutics operates as a biotechnology research company that develops biopharmaceuticals for treating allergies and mast cell-mediated diseases. In December 2025, Allegria Therapeutics AG raised USD 5. 1 million in seed funding led by ALK-Abello, with participation from HighLight Capital, Lichtsteiner Foundation and Forty51 Ventures The round was part of a larger USD 8. 6 million seed round.
The firm develops and offers proprietary therapeutic approaches for mast cell-mediated diseases. Mast cells play a crucial role in allergy and inflammatory conditions. The company generates revenue from providing biotech research services and engaging in R&D collaborations focused on mast cell diseases. The company will use the December 2025 funding to advance its Physical AI platform, automate drug discovery workflows, and integrate robotics and AI systems for continuous learning and large-scale experiments.
Current Investors
Forty51 Ventures, ALK-Abello, HighLight Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
https://allegriatx.com/
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.